Back grey_arrow_rt.gif
 
 
Janssen Launches New HCV Support for Patients
 
 
  zenopa.com/

Janssen has introduced a new support programme for hepatitis C patients with the aim of promoting healthy living and treatment adherence.

The MyIncivo scheme will be run in partnership with Bupa Home Healthcare and is tailored for patients using Janssen's drug Incivo (telaprevir), along with Roche's Pegasys and Copegus.

Elements of the programme include SMS alerts for dosage reminders and guidance on possible Incivo side effects, as well as general advice on how diet and lifestyle improvements can help to deal with the condition, reports InPharm.

It is designed to complement the care offered by patients' hepatitis C specialist doctors, as well as being accessible to partners, carers or family members.

Dr Peter Barnes, medical director at Janssen, said: "We are launching this programme to support patients 24 hours a day, seven days a week for the full duration of their treatment if they are initiated on a telaprevir-based treatment regimen."

Last month, the company formed a new partnership with Forma Therapeutics, which will see the two organisations jointly developing and commercialising cancer therapies.

---------------------

Medivir Vies For Spot In Narrow Hepatitis C Market

LONDON (Dow Jones)--Hepatitis C, a harrowing infection that leads to the inflammation of the liver, is a virus of pandemic size that has attracted the attention of some of the world's biggest drug makers.

But Sweden's small biotech Medivir AB (MVIR-B.SK) says it intends to be a major player in treating the disease, and predicts the market will ultimately have room for just four or five products.

"It is simply a question of which drug will have the biggest share of the market", Medivir's executive vice-president of corporate affairs Rein Piir told Dow Jones Newswires in an interview.

And in protease inhibitor TMC435, Piir believes Medivir has found its winner.

Piir says there is nothing in development that's better than TMC435, which is currently in global Phase III trials and which Medivir expects to launch by the end of next year.

Danske Banke analyst Hans Jeppsson agrees.

Jeppsson regards TMC435 as being the best-in-class protease inhibitor, which prevents viral replication by inhibiting the activity of protease enzymes. Final judgment will need to await results from two combination trials the drug is currently undergoing, he adds.

 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org